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Abstract
LEDGF/p75 can tether over-expressed lentiviral integrase proteins to chromatin but how this underlies its integration
cofactor role for these retroviruses is unclear. While a single integrase binding domain (IBD) binds integrase, a complex N-
terminal domain ensemble (NDE) interacts with unknown chromatin ligands. Whether integration requires chromatin
tethering per se, specific NDE-chromatin ligand interactions or other emergent properties of LEDGF/p75 has been elusive.
Here we replaced the NDE with strongly divergent chromatin-binding modules. The chimeras rescued integrase tethering
and HIV-1 integration in LEDGF/p75-deficient cells. Furthermore, chromatin ligands could reside inside or outside the
nucleosome core, and could be protein or DNA. Remarkably, a short Kaposi’s sarcoma virus peptide that binds the histone
2A/B dimer converted GFP-IBD from an integration blocker to an integration cofactor that rescues over two logs of
infectivity. NDE mutants were corroborative. Chromatin tethering per se is a basic HIV-1 requirement and this rather than
engagement of particular chromatin ligands is important for the LEDGF/p75 cofactor mechanism.
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Introduction
HIV-1 and other retroviruses use encoded integrase (IN)
enzymes to catalyze permanent insertion of a cDNA copy of the
viral genome into host DNA in each replication cycle [1].
Experiments with model DNA targets have defined the essential
DNA-recombining steps. However, the process within the cell
nucleus, where the viral pre-integration complex must negotiate
nuclear transit, then access and insert into a chromosome,
remains undefined in many respects [2]. Each of the two
reaction participants is a complex macromolecular assembly and
the chromatin fiber is also the site of numerous intricate
processes, including transcription, DNA replication and diverse
DNA repair activities, each of which involves formation of
multi-protein machineries. Nuclear proteins have long been
suspected to participate in retroviral integration [3] and recent
studies have identified LEDGF/p75 as a lentivirus-specific
replication cofactor [4–13]; see [14] and [15] for current
reviews. LEDGF/p75 depletion impairs HIV-1 integration
[7,9,12] and over-expression of the IBD produces substantial
dominant-interfering activity [7,8]. LEDGF/p75 has also been
found to be a key determinant of the lentiviral bias for
integration into transcription units [6,12,13]. Its normal cellular
role appears to be modulating Pol II transcription, although this
remains provisionally established, with the mechanism unknown
[16].
Cofactor models currently conceive of LEDGF/p75 linking IN
to unknown chromatin components. If lentiviral INs are over-
expressed outside the viral context, they accumulate on chromatin
[4,5,17–19] where they remain attached throughout the cell cycle
[19]. Stable LEDGF/p75 knockdown shifts IN entirely to the
cytoplasm [18]. LEDGF/p75 also protects IN from proteasomal
degradation [20]. This latter stabilization effect is separable from
chromatin tethering (it occurs in the cytoplasm with NLS-mutants
or chromatin binding mutants of LEDGF/p75) and is insufficient
for cofactor activity [7].
Interactions with chromatin and IN have been mapped to the
LEDGF/p75 N- and C-terminal regions respectively (Figure 1A).
The single, structurally discrete IN binding domain (IBD) is
situated C-terminally [19,21] and consists of four alpha helices
[22]. Two inter-helical loops extend to interact with the IN core
catalytic domain dimer interface [23] and one loop also interacts
with the IN N-terminal domain [24]. In contrast to the IBD, the
chromatin-binding end of the virologically functional tether is
much less defined and its ligands are unknown. Chromatin
attachment is mediated by a complex N-terminal domain
ensemble (NDE), which occupies most of LEDGF/p75, up to
residue 325 [25]. Minimally it includes a PWWP domain, the
nuclear localization signal (NLS), a charged region 1 (CR1), and
an A/T hook domain composed of two A/T hook elements
[25,26]. Deletion and domain transfer experiments suggest
complex synergy of the various NDE elements, with the two most
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pair (Figure 1A). Deleting the PWWP domain disrupts LEDGF/
p75 association with condensed chromosomes in mitosis [25].
Analyzed alternatively by biochemical analysis of sub-cellular
fractions, PWWP domain deletion impairs high affinity chromatin
association but additional deletion of the A/T Hook domain is
required to abolish it [25]. The PWWP domain in conjunction
with an adjacent region of 49 relatively charged amino acids (CR1)
suffices to tether GFP to condensed chromosomes, but transfer of
Triton-resistant binding to GFP is negligible without addition of
the A/T hook pair [25]. Two additional relatively charged regions
(CR2 and CR3) have no autonomous chromatin binding activity
but appear to cooperatively enhance dominant effects of the other
NDE elements, with full Triton-resistance achieved only when the
donor to GFP extends from the N-terminus of LEDGF/p75
through CR3 [25]. Finally, the NLS region has also been reported
to contribute to chromatin association [26].
Depletion of LEDGF/p75 clearly impairs the intra-nuclear
progress of HIV-1 towards the integrated state, but the mechanism
of the cofactor assistance the protein provides is unclear. Lacking
explanation also is the evolutionary pressure driving strict
conservation of LEDGF/p75-IN binding among all lentiviruses,
yet only lentiviruses, despite substantial sequence variation in the
IN dimer interfaces of the primate, feline, and ungulate lentivirus
groups. A mutant deleted of the PWWP and A/T hook domains
lost all chromatin association and was unable to rescue HIV-1
replication in LEDGF/p75-depleted cells [7], as did a similar
mutant in murine knockout cells [12]. However, whether
chromatin attachment per se is the necessary and sufficient
mechanism in vivo is unknown. The question is compounded by
limited understanding of the individual NDE elements and their
natural roles [27,28]. Our goal here was to test the chromatin
tethering hypothesis explicitly. We sought also to discriminate
between two models of LEDGF/p75 action. The first posits NDE-
specific functional roles in enabling integration. The alternative
scenario is one in which the primary role for LEDGF/p75 reflects
its ability to meet two criteria: binding chromatin strongly and
possessing a domain (the IBD) to which lentiviral IN proteins could
evolve high-affinity binding without unsolvable constraints on their
catalytic or other viral functions. If the latter is the case, it could
signify a general requirement for which other retroviral genera
Author Summary
Like other retroviruses, HIV-1 integrates a DNA copy of its
genome into a host cell chromosome in each replication
cycle. The resulting integrated proviruses are the basis for
two important clinical problems: the inability to eradicate
HIV-1 from the body and the permanent archiving of drug-
resistant viruses. The DNA recombining steps catalyzed by
the viral integrase are known, but the process as it occurs
between the incoming virus and chromatin in cells is
incompletely understood. LEDGF/p75 has been identified
as an HIV-1 integration cofactor. If integrase is over-
expressed in the absence of other viral components, it
becomes linked to chromatin via LEDGF/p75. Whether this
chromatin attachment function is the necessary and
sufficient basis for its cofactor role in the viral life cycle
has been unclear. The current work shows that HIV-1
cofactor function is preserved if the chromatin binding
modules of LEDGF/p75 are replaced with widely disparate
chromatin linkages. These results are evidence that
chromatin tethering per se rather than connections to
specific chromatin ligands is central to the LEDGF/p75
mechanism. They also have implications for targeting of
lentiviral vectors within the human genome.
Figure 1. LEDGF/p75 and chimeric derivatives. Lengths of protein elements are drawn to scale. (A) Human LEDGF/p75 is shown with domains
that have been identified. For LANA31-p75
P-/DAT2R, the N-terminal 31 amino acids of the 1,162 amino acid KSHV LANA protein were fused in frame to
p75
P-/DAT2R. The latter consists of residues 94–530 of LEDGF/p75 with each A/T hook element also disabled by glycine substitution (red dot) of a
functionally critical arginine [69]. The sequence of the LANA31 peptide is MAPPGMRLRSGRSTGAPLTRGSCRKRNRSPE. The first 23 residues (underlined)
bind to the groove formed by adjacent molecules of core histone 2A and core histone 2B in the nucleosome core [29]. Note that all elements in the
chimera retain native context polarity with respect to amino and carboxy termini. All constructs have 7 synonymous nucleotide changes at the RNAi
target site. LEDGF/p52 (top) is the other splice variant of this gene. 333 amino acids in length, it has the same N-terminal 325 amino acids of LEDGF/
p75 but lacks IN interaction, since a different 8 amino acid C-terminus (yellow segment) replaces residues 326–530 of LEDGF/p75. AT: A/T hook pair;
CR1-3: charged regions 1–3; NLS: nuclear localization signal; NN : mutant AT hook; NDE: N-terminal domain ensemble involved in chromatin binding.
(B) Linker histone chimeras. GFP-199-530 lacks the PWWP, AT hooks and NLS of LEDGF/p75; it does not bind chromatin [25] and is used as a control
here. Linker histone (H1.1 and H1.5) chimeras A–F are illustrated. GFP–H1.1–199-530 and GFP–H1.5–199-530 (chimeras E and F) were eventually the
most studied in viral replication experiments. A Ser-Gly-Gly-Gly-Gly-Ser (Ser-Gly4-Ser) linker was used as illustrated. All constructs have 7 synonymous
nucleotide changes at the RNAi target site (illustrated for GFP-199-530). See Table 1 for a comparison of the properties of H1 and LANA31.
doi:10.1371/journal.ppat.1000522.g001
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cially if their IN proteins are constrained on functional grounds
from evolving dimer interfaces that bind the IBD. We replaced the
LEDGF/p75 NDE with selected, divergent chromatin binding
modules: two variants of the human linker histone H1 and a 31
amino acid peptide derived from the amino terminus of Kaposi’s
sarcoma herpes virus (KSHV) latency associated nuclear antigen
(LANA) [29]. These elements were chosen for particular criteria.
They are unrelated to any LEDGF/p75 domains and are well-
characterized at the molecular level. H1 and the KSHV LANA
peptide also differ strongly in evolutionary origin, natural role, size
and structure. Their chromatin ligands contrast sharply as well:
H1 binds outside the nucleosome, to DNA, while the LANA
peptide binds inside the nucleosome core, to protein. We
hypothesized that fusion of one or more of these chromatin-
binding domains to C-terminal regions of LEDGF/p75 that
contain the IBD could result in chimeric proteins that would
rescue HIV-1 IN tethering and HIV-1 infection in CD4+ human
T cells that are LEDGF/p75-deficient and/or express interfering
IBD fragments. We additionally tested NDE-mutants of LEDGF/
p75. Our results show that neither a specific chromatin ligand, nor
even a basic location or molecular class of ligand within the
chromatin fiber is required.
Results
H1 and LANA31 confer high-stringency chromatin
binding to LEDGF/p75 C-terminal segments
Histones are of two general types. The four core histones (H2A,
H2B, H3 and H4) form a protein octet at the center of each
10 nM diameter nucleosome, the basic unit of chromatin. In
contrast, the linker histone H1 binds externally, to the stretch of
DNA entering and exiting each nucleosome [30,31]. In the
absence of H1, the nucleosome consists of 147 base pairs of DNA
wrapped around the octet in 1.65 super-helical turns, while in its
presence the resulting ‘‘chromatosome’’ contains two complete
turns, with 168 bp of DNA [32–34]. The bending and fastening of
DNA fosters higher-order coilings e.g., the 30 nm fiber comprised
of 6–8 nucleosomes. We prioritized H1 as a chromatin-binding
module for several reasons. Mammalian eukaryotic chromatin
contains approximately 0.5–1.0 histone H1 molecules per
nucleosome, with a 1:1 stoichiometry reported for lymphocytes
[35–37]. This chromatin-associated protein is thus ubiquitous yet
situated external to the nucleosome core [36,38–41]. In addition,
GFP-H1 fusions are known to retain normal chromatin interaction
[33,39] and cells are broadly tolerant of manipulations or even
knockouts of individual H1 variants [31]. Finally, H1 histones
exchange among chromatin binding sites in both condensed and
uncondensed chromatin [38,39]. We predicted this would allow
introduced chimeras to achieve dynamic equilibrium with
endogenous H1 molecules. Six human H1 variants with varying
chromatin mobility exist [42]. Of these, we selected H1.1 and
H1.5 because they represent the ends of this mobility spectrum
with H1.1 having the fastest off rate and H1.5 the slowest [33]. Six
H1 chimeras (chimeras A–F, Figure 1B) were made by placing
amino acids 199–530 of LEDGF/p75 within three different in-
frame permutations with GFP and either human H1.1 or H1.5. In
chimeras E and F, GFP-tagged H1.1 and H1.5 are situated N-
terminally, mimicking the location of the LEDGF/p75 chromatin
binding domain ensemble. To allow expression in cell lines with
potent stable RNAi against LEDGF/p75, all constructs have 7
synonymous mutations in the shRNA target sequence [7,19].
Chimeras A–F and several control proteins were analyzed by
immunoblotting, biochemical fractionation, and confocal imaging.
Sub-cellular fractionation following a well-characterized protocol
[7,25] revealed that all six H1.1 or H1.5 chimeras are of predicted
size and are found in the strongly chromatin-bound (S2) fraction,
which is Triton-resistant and requires DNAse and salt treatment to
mobilize (Figure 2A). Thus, the proteins display high-stringency
chromatin association similar to LEDGF/p75. Control analyses
showed this required the H1 moiety (Figure 2A, see GFP-199-
530). While such biochemical assays average the properties of cells
in all cell cycle phases, confocal imaging confirmed each chimera
to be nuclear and documented association with both uncondensed
and condensed mitotic chromatin (Figure S1A). In this respect
they behaved identically to GFP-H1.1 and GFP-H1.5, while
proteins lacking the linker histone, such as GFP-199-530, were un-
associated with chromosomes.
LANA31, the 31 N-terminal amino acids of the KSHV LANA
protein [29], was then used to establish an informative contrasting
linkage with chromatin. Table 1 summarizes comparisons of this
peptide with histone H1. KSHV is a gamma-herpes virus that
achieves latency by persisting as a DNA episome [43]. LANA links
repeats in the centromere-lacking episome to chromatin, enabling
it to partition with the host cell genome at mitosis [44]. However,
only the 23 N-terminal residues of the 1,162 amino acid KSHV
LANA protein establish the chromatin linkage, via a tight hairpin
structure formed by residues 5–13 that inserts with high specificity
into a groove formed between core histones 2A and 2B [29]. Thus,
in contrast to H1, this peptide binds inside the nucleosome core,
and to a protein rather than nucleic acid ligand. We fused the
LANA31 peptide in frame to the N-terminus of p75
P-/DAT2R
(Figure 1), a LEDGF/p75 mutant that retains the LEDGF/p75
NLS and is nuclear, but lacks detectable chromatin association
because the PWWP domain is deleted and each A/T hook is
disabled by glycine substitution of a critical arginine residue [25].
As shown in Figure 2B, p75
P-/DAT2R segregated in the non-
chromatin bound (S1) fraction whereas the addition of LANA31
caused strict, S2-fractionating chromatin association. This was cell
cycle-resilient, as immunofluorescence analyses confirmed con-
densed and uncondensed chromatin association was conferred by
the peptide (Figure S1B).
Chimeras tether IN to chromatin
To be capable of reconstituting LEDGF/p75 function, the H1
and LANA31 chimeras should at a minimum rescue chromatin-
tethering of over-expressed HIV-1 IN. The H1 chimeras did so
(Figure 3C), producing confocal imaging patterns similar to full-
length LEDGF/p75 (Figure 3A). H1 chimeras E (GFP-H1.1-199-
530) and F (GFP-H1.5-199-530) consistently displayed the strictest
phenotype in repeated experiments, with no un-tethered IN
remnant, and are compositionally the most straightforward.
Therefore they were utilized for subsequent work. In contrast to
the H1 chimeras, GFP-H1.1 and GFP-H1.5 bound chromatin but
failed to relocate IN, indicating that the IBD linkage is necessary
(Figure 3B). Mutation of LEDGF/p75 Asp366 to Asn (D366N) is
known to specifically disrupt interaction of the IBD with the HIV-
1 IN dimer by removing a critical negative charge involved in
polar interactions with the connector peptide linking IN alpha
helices 4 and 5 [23]. When introduced into the chimeric histone
proteins, this single amino acid change left their chromatin-
binding properties unchanged but resulted in failure to re-localize
IN, confirming specificity further (Figure 3C).
LANA31-p75
P-/DAT2R also tethered IN to chromatin, again
throughout the cell cycle (Figure 3E). However, LANA31-
p75
P-/DAT2R and its associated IN displayed a different chromatin
association pattern than H1.1- or H1.5-tethered IN, producing a
more variegated, punctate appearance (Figure 3E). In contrast, the
LEDGF/p75 Cofactor Mechanism
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P-/DAT2R protein displayed a homogeneously diffuse
nuclear pattern (compare Figures 3D & 3E). Note also that IN is
still nuclear-trapped by the latter chimera (which retains the
LEDGF/p75 NLS) but is not chromatin-trapped and remains un-
tethered without the LANA31 peptide (Figure 3D).
The specific interaction of the histone constructs with HIV-1 IN
was further confirmed by co-immunoprecipitation (Figure 4A).
Note that the GFP-H1.5-199-530
D366N mutant also consistently
pulled down HIV-1 IN, albeit much less than GFP-H1.5-199-530.
We speculate that one or more additional mutations, e.g., F406A,
may be needed to eradicate all detectable interaction of these
proteins with IN [22]. We showed previously that LEDGF/p75
protects lentiviral IN proteins from proteasomal degradation, a
property that is dependent on IBD-binding but not on chromatin
binding or on the cellular location of the IBD-IN interaction [20].
Using the previously validated IN stability rescue assay [20], we
found that artificially chromatin-tethered chimeras also protected
IN protein from proteasomal degradation (Figure 4B). GFP-H1.1
or GFP-H1.5 had no effect, but each of the chimeric proteins was
able to protect IN similarly to LEDGF/p75 (Figure 4B). This
protection effect can also be discerned by comparing Figure 3B
with Figure 3C–E. GFP-H1.1 and GFP-H1.5 do not rescue IN
Figure 2. Chromatin binding assays. (A) H1 chimeras are stringently chromatin bound. The sub-cellular fractionation scheme is summarized in
the diagram. See Materials and Methods for details and [25] for complete assay validation with varied control proteins. Here the S1 and S2 fractions
are shown. The H1 chimeras A–F and GFP-H1.1 and GFP-H1.5 were detected with anti-GFP. Chimeras A–F had predicted molecular mass (,93 kDa) as
did GFP-H1.1 and GFP-H1.5 (,57 kDa). GFP199-530 displays no chromatin binding and like GFP is found in the S1 fraction. LEDGF/p75 is tightly
chromatin bound and fractionates solely to S2. (B) Addition of the LANA31 peptide to the N-terminus of p75
P-/DAT2R converts it to a chromatin
binding protein found in S2.
doi:10.1371/journal.ppat.1000522.g002
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providing additional IN by transient transfection (bottom row of
panel 3B).
Taken together, these experiments demonstrate bona fide IN-
to-chromatin tethers that link to IN via an IBD that is functionally
normal (i.e. it both binds IN and protects it from degradation in
cells), bind chromatin throughout the cell cycle, yet also produce
different local intra-chromatin distributions that can even be
distinguished by their confocal microscopic patterns.
Rescue of HIV-1 infection by chimeric proteins
We next tested effects of chimeric proteins on HIV-1 replication
in LEDGF/p75-depleted CD4+ human T cell lines. Table S1
summarizes cell line characteristics. The magnitude of the HIV-1
block in these cells correlates with establishing that the Triton X
100-resistant chromatin fraction is stripped of endogenous
LEDGF/p75 [7]. Viral blocks map to integration and are rescued
by LEDGF/p75 re-expression but not by LEDGF/p75 deletion
mutants lacking either chromatin binding or IBD function [7].
Here, chimeric proteins were expressed in TL3 cells and a paired
control shRNA line (TC3 cells) as previously described [7]. The
H1-based fusion proteins GFP–H1.1–199-530 and GFP–H1.5–
199-530 both rescued single round infectivity as assessed 5 days
after infection with HIV-1 luciferase reporter virus
(Figure 5A).Time course analysis indicated similar degrees of
rescue whether luciferase was analyzed at 24 hours (Figure S2A),
or at two months (Figure S2B). Chromatin fractionation confirmed
persistent S2 fraction-negativity for endogenous LEDGF/p75 and
that the introduced GFP-H1.1-199-530 and GFP-H1.5-199-530
proteins segregated with the S2 fraction (Figure 5B, both S1 and
S2 fractions are shown in Figure S2C). Moreover, H1 chimeras
had rescuing activity equivalent to LEDGF/p75 itself (Figure 5C)
and Alu-PCR integration assays showed integration rescue
(Figure 5D).
We next tested the LANA31-p75
P-/DAT2R chimera for its
rescuing function and introduced into the analyses the effect of all
of the chimeras on not just LEDGF/p75 depletion but also on
IBD-mediated dominant interference. Over-expression of the IBD
inhibits HIV-1 integration [7,8,11]. In such experiments, the IBD
has been expressed as a GFP-IBD fusion protein because it is
unstable alone (data not shown). Combining stringent lentiviral
vector-mediated RNAi knockdown of LEDGF/p75 with GFP-
IBD in stable human T cell lines strikingly diminishes HIV-1
infectivity, by over three logs, a high dynamic range that fosters
stringent testing of rescue capability (Figure S3). Accordingly,
chimeric and control proteins were compared for ability to rescue
HIV-1 infectivity defects produced by RNAi alone, GFP-IBD
alone, and RNAi plus GFP-IBD in combination. Results are
collected and compared as fold-rescue data in Figure 6 LANA31-
p75
P-/DAT2R substantially rescued viral infection in the presence of
RNAi and competed with the GFP-IBD in GFP-IBD cells,
similarly to the H1 chimeras. LANA31-p75
P-/DAT2R effected a two
log rescue in TL4 cells. In contrast, rescue by the parental protein
(p75
P-/DAT2R) was minimal. The H1 and LANA chimeras were
confirmed to segregate to the chromatin bound S2 fractions of
these stable cell lines, while GFP-IBD was in S1 (Figure S4A and
B). The ability of H1 and LANA31 chimeras to reverse GFP-IBD
dominant interference suggested that it is the location of the IBD
that determines its effect, a point we address further in the next
Results section. Note that a small yet consistently observed
rescuing effect could be detected with a chromatin-tethered
D366N mutant (e.g., the effect of GFP-H1.1-199-530
D366N in TL3
cells, Figure 6). This effect is consistent with the minimal yet
detectable residual interaction between IN and the D366N mutant
chimeric protein seen in co-immunoprecipitation experiments
(Figure 4A). Similarly, the slight rescue capacity of p75
P-/DAT2R,
though consistently observed, was superseded 50-fold by
the LANA31 version of this protein (Figure 6). The residual
p75
P-/DAT2R activity may reflect slight chromatin binding activity
we have not been able to detect biochemically. Note also that these
graphs report the aggregate data for specific cell lines. In
individual experiments, up to 15- and 158-fold rescues were seen
for LANA31-p75
P-/DAT2R in the TL3 and TL4 cell lines
respectively.
LANA31 peptide-mediated reversal of profound antiviral
effects of combined LEDGF/p75 RNAi and IBD dominant
interference
The above experiments suggested chromatin attachment per se,
rather than interaction with a particular ligand, is the critical
function mediated by LEDGF/p75. We then asked whether a
truly minimal tether consisting of a heterologous chromatin
connector linking only the IBD and no other LEDGF/p75
segments to chromatin would support HIV-1 replication. Re-
markably, simply fusing the LANA31 peptide to GFP-IBD
(Figure 7A) changed the phenotype of this protein from an
integration-inhibiting protein to an integration cofactor capable of
rescuing over two logs of HIV-1 infectivity (Figure 7C,D). In fact,
these minimally tethered IBD constructs were more effective in
reversing RNAi or GFP-IBD effects than the more elaborate H1
or p75
P-/DAT2R constructs (Figures 6 and 7). Corroborating the
results, LANA31-GFP-IBD tethered HIV-1 IN to chromatin as
revealed by both microscopy and biochemical fractionation while
GFP-IBD alone interacted with IN without tethering it (Figure 7A,
B). Note also that LANA31-GFP-IBD is less abundant in the cells
than GFP-IBD (Figure 7A), yet it effectively rescued HIV-1 from
the profound antiviral effects of the RNAi+GFP-IBD combination.
Figure 7C shows one such experiment, while Figure 7D shows
Table 1. Comparison of Substitute Chromatin Binding Modules.
Linker Histone (human H1.1 and H1.5) LANA31 peptide
N Intra-chromatin ligand is DNA [36,41]. N Intra-chromatin ligand is protein [29].
N Binds outside nucleosome [38]. N Binds inside nucleosome [29].
N Primary functions are diverse, include regulating nucleosome architecture [36]. N Primary function is chromatin-tethering of a large DNA virus genome [29,44].
N Size approximately equal to p75 NDE [36]. N About 10 times smaller than p75 NDE [29].
N Well-characterized, known to maintain phenotype as GFP fusion [38]. N Well-characterized, known to tether GFP to chromatin [29].
N Variants with different chromatin on-off rates (H1.1 fast, H1.5 slow) [33]. N No variants [29].
doi:10.1371/journal.ppat.1000522.t001
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PLoS Pathogens | www.plospathogens.org 5 July 2009 | Volume 5 | Issue 7 | e1000522Figure 3. IN tethering by H1 and LANA31 chimeras. (A) Intracellular location of HIV-1 IN. Confocal micrographs of LH4 cells are shown. These
cells stably express HIV-1 IN (red) and are also stably depleted of LEDGF/p75 by shRNA expression. When LEDGF/p75 is re-expressed in LH4 cells with
an shRNA-resistant cDNA (right), HIV-1 IN re-localizes to the nucleus as a chromatin-tethered protein. Data not shown reveals two additional aspects:
(i) re-expressed LEDGF/p75 co-localizes tightly with IN; (ii) detector gain is higher (,1000) in the absence of LEDGF/p75 on left, compared with ,600
in the (+) LEDGF/p75 images at right because IN is much more abundant. Some mitotic cells are pointed out with circles. (B) GFP-H1.1 (top panel
row) proteins expressed in LH4 cells are chromatin-bound but do not interact with HIV-1 IN. Mitotic cells are circled. The stably expressed IN is poorly
visualized because it is not protected as in C–E. For this reason, the lower two panel rows show GFP-H1.5 with additional IN co-transfected to facilitate
imaging. (C) IN tethering. H1 chimeras E and F tether IN to chromatin but E
D366N and F
D366N do not. Note again that additional IN was transiently
cotransfected with the D366N mutants to facilitate imaging. Mitotic cells are circled. Chimeras A, B, C and D produced the same results in about 90%
of cells, although in contrast to chimeras E and F, slight non-overlap of GFP and IN signal was detected in occasional cells (data not shown). (D,E)
p75
P-/DAT2R binds HIV-1 IN and traps it in the nucleus, but does not tether it to chromatin. In contrast the LANA31-p75
P-/DAT2R tethers. Note discrete
foci of LANA31-p75
P-/DAT2R in interphase nuclei in E. Mitotic cells are circled.
doi:10.1371/journal.ppat.1000522.g003
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LANA31-GFP-IBD
D366N produces a very small rescue effect as
shown, but this is dwarfed by the more than two log effect of
LANA31-GFP-IBD. Alu PCR confirmed rescue at the level of
integration specifically (Figure 7E). In addition, 2-LTR circle levels
were equivalent (varying less than 2-fold, data not shown),
suggesting that nuclear import is unaffected (and assuming that
circular forms have equivalent nuclear stability in the presence of
GFP-IBD). To exclude the possibility that the two GFP-IBD
proteins were interacting with each other with LANA31-GFP-IBD
recruiting GFP-IBD to chromatin, we constructed and co-
expressed IBD fusions with GFP spectral variants (Figure S5). In
addition, immunoblotting of S2 fractions (Figure S6), and real-
time quantitative RT-PCR (Figure 7F) on the cell lines expressing
the LANA31-GFP-IBD chimeras confirmed no rebound of
endogenous LEDGF/p75 expression over the parental TL4 cell
lines. These experiments in Figure 7 eliminate all of LEDGF/p75
except for the IBD from cells, with the only variable being the
LANA peptide, thus excluding essential roles for any NDE
components. They indicate that it is the location of the IBD – in a
chromatin-tethered state – that determines the direction of its
effect on HIV-1 infection.
Chimeric proteins support replicating HIV-1 infection
We further examined if these chimeras would function similarly
in the context of spreading HIV-1 infection. TL3 cells expressing
GFP-H1.1-199-530 were challenged with wild type HIV-1 at MOI
of 0.01. As observed previously [7], infection was markedly
delayed in TL3 cells, with peak p24 detectable at day 23 compared
to control TC3 which peaked at day 9 (Figure 8A). In contrast,
more rapid spreading infection occurred in cells expressing GFP-
H1.1-199-530 as evidenced by peak p24 detectable at day 11. We
also examined the efficacy of LANA31-GFP-IBD in replicating
infection as shown in Figure 8B. In control TL4 and TL4 cells
with LANA31-GFP-IBD
D366N no p24 was detectable at day 55
consistent with profound inhibition of HIV-1 in these cells.
Strikingly, LANA31-GFP-IBD rescues infection in TL4 cells to a
level similar to that seen in cells that express only GFP-IBD, with
peak p24 detected at day 20 in both. Thus, chimeric LEDGF
proteins recapitulate wild type LEDGF functions, supporting
single round and replicating HIV-1 infections.
Function of chimeric proteins in LEDGF/p752/2 mouse
embryonic fibroblasts
Two groups have generated LEDGF/p75 knockout mice
[12,45]. HIV-1 integration is impaired approximately 5–10 fold
in LEDGF/p752/2 mouse embryonic fibroblasts (MEFs), and
LEDGF/p75 depletion alters lentiviral integration profiles to a
similar extent in mouse and human cells [6,12,13]. Murine
LEDGF/p75 thus appears to function similarly to human
LEDGF/p75, in directing integration towards active genes. Here
we examined if the behavior of the chimeric proteins would be
consistent between human T cells and MEFs. Heterochromatin in
mouse cells exists as large pericentric blocks that stain intensely
with DAPI [46]. GFP-H1.1-199-530, although it remains attached
to chromatin through mitosis (Figure 9A), did not overlap tightly
with DAPI in MEFs, consistent with the known preferential
binding of H1.1 to euchromatin in mouse cells [33]. 2/2 MEFs
were transfected with GFP-H1.1 or GFP-H1.1-199-530, and
challenged with HIV-1 reporter virus. Subcellular fractionation
and western blotting confirmed the majority of the transfected
proteins to be chromatin bound (Figure 9B, S2 fractions of
transfected MEFs). HIV-1c-luc expression was approximately 6
fold less in 2/2 MEFs compared to +/+ MEFs (Figure 9C). GFP-
Figure 4. Chimeric proteins co-imunoprecipitate with HIV-1 IN
and protect it from proteasomal degradation. (A) Co-immuno-
precipitation with Myc-tagged HIV-1 IN. Proteins were immunoprecip-
itated with anti-GFP and immunoblotting was performed with anti-Myc.
The positive control GFP199-530 pulls down HIV-1 integrase, as does H1
chimera F (GFP-H1.5-199-530). Prolonged over-exposure yielded a faint
detectable IN band in the F
D366N lane (panel to right), with less than 1%
of the F protein band intensity, suggesting slight residual interaction
between IN and F
D366N. (B) Chimeras protect HIV-1 IN in an IN stability
rescue assay in LH4 cells. These cells are 293T cells that (i) are knocked
down for endogenous LEDGF/p75 and (ii) contain a stably integrated
HIV-1 IN expression plasmid [20]. In the absence of LEDGF/p75, only low
IN levels are detectable (lanes 1 and 7). IN is protected by re-expression
of LEDGF/p75 (p75syn7, lanes 2 and 8) or proteins that contain the
LEDGF/p75 IBD (H1 chimeras A–E in lanes 3–5 and 9–11). In contrast,
neither GFP-H1.1 or GFP-H1.5 protect (lanes 6 and 12).
doi:10.1371/journal.ppat.1000522.g004
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PLoS Pathogens | www.plospathogens.org 7 July 2009 | Volume 5 | Issue 7 | e1000522Figure 5. Rescue of HIV-1 infection. (A) SupT1 based cell lines stably expressing H1 chimeras were challenged with VSV-G pseudotyped HIVluc.
(B) Cellular fractionation of stable cell lines confirms expression of the H1 chimeras in the S2 fraction and that there is no detectable LEDGF/p75 in
the TL3-derived cell lines. (C) Rescue is comparable to that achieved by LEDGF/p75 re-expression (p75syn7). Error bars reflect duplicate
measurements in each experiment. (D) Integration assessed by Alu PCR.
doi:10.1371/journal.ppat.1000522.g005
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MEFs approximately 3.7 fold, whereas less luciferase activity was
detected in 2/2 MEFs transfected with GFP-H1.1. Thus, the
chimera functions similarly in human and mouse LEDGF/p75-
deficient cells.
Properties of LEDGF/p75
PWWP-
Finally, our experiments support a prediction that LEDGF/p75
cofactor activity does not require interaction of its PWWP domain
with particular chromatin ligands. To test this in a non-chimeric
setting, we employed LEDGF/p75
PWWP-, a PWWP domain-
deletion mutant (Figure 10). This mutant specifically loses mitotic
chromatin binding, but it retains strong chromatin binding activity
in other cell cycle phases, resulting in its approximately equivalent
segregation into S1 and S2, compared to the strict S2 partitioning
of LEDGF/p75 [25]. Both properties were re-verified here
(Figure 10A,C). Consistent with this, LEDGF/p75
PWWP- was less
resistant to salt extraction than LEDGF/p75 (Figure 10B). Stable
TL3-based cell lines were derived and HIV-1 reporter virus
challenges showed LEDGF/p75
PWWP- exhibited 44.2+/26.5% of
the rescue activity of wild type LEDGF/p75 (Figure 10D). Thus,
the nearly 50% rescue afforded by this PWWP-deleted mutant
exactly parallels its chromatin fractionation properties (Figure10E).
Note that further deleting the A/T hook domain from LEDGF/
p75
PWWP- results in a protein with no S2 fraction association
(Figure 2A) and no HIV-1 rescuing function [7].
Discussion
Our results establish chromatin tethering per se as a necessary
and sufficient requirement for efficient lentiviral integration and
provide further direct evidence that this is the main mechanism of
LEDGF/p75 cofactor function in the HIV-1 life cycle. The data
work against cofactor models that depend substantially on specific
NDE domain interactions with chromatin ligands or on these
domains interacting with the IBD region as a functionally
Figure 6. Chimeric proteins rescue infection. Results summarizing multiple experiments are shown as fold rescue over baseline of HIV-1luc with
the respective chimeras in TL3, GFP-IBD or TL4 cell lines, with the un-rescued cell line values set at 1.0. Experiments were repeated 2–6 times and
means+/2S.D. are shown. In TL3 cell-derived lines, some rescue was seen with D366N mutant H1 chimeras, consistent with its markedly impaired but
still detectable IN interaction (Figure 4A). LANA31-p75
P-/DAT2R had similar activity compared to the histone chimeras. TL4 cells express the GFP-IBD
dominant interfering protein as well as RNAi against endogenous LEDGF/p75. LANA31-p75
P-/DAT2R rescued the infectivity defect .two logs in these
cells, in contrast to the mutant p75
P-/DAT2R. The fourth column group shows effects of introductions into control TC3 cells, indicating that there is no
effect on the viral life cycle when these proteins are introduced without either LEDGF/p75-specific antiviral maneuver (knockdown or dominant
interfering protein).
doi:10.1371/journal.ppat.1000522.g006
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PLoS Pathogens | www.plospathogens.org 9 July 2009 | Volume 5 | Issue 7 | e1000522Figure 7. LANA31-GFP-IBD reverses effect of combined LEDGF/p75 depletion and GFP-IBD dominant interference. (A) GFP-IBD and
LANA31-GFP-IBD. Amino acid numbers correspond to their position in wild type LEDGF/p75. LANA31-GFP-IBD was expressed by a retroviral vector in
TL4 cells. TL4 cells are highly refractory to HIV-1 infection because they simultaneously express GFP-IBD and an endogenous LEDGF/p75-eradicating
shRNA [7]. Subcellular fractionation and immunoblotting of resulting stable cell lines with GFP antibody shows GFP-IBD is mainly in S1 while LANA31-
GFP-IBD is mainly in S2. The greater levels of GFP-IBD protein compared to the rescuing LANA31-GFP-IBD reflect that expression of the latter was
selected by a co-encoded G418 resistance in an MLV-based retroviral vector, which tends to select for a minimal expression level needed to make
cells drug stable, while GFP-IBD is encoded from a CMV promoter in a lentiviral vector followed by GFP-enrichment by FACS. (B) Confocal microscopy
of LH4 cells transfected with GFP-IBD or LANA31-GFP-IBD are shown in B(i). (See legend to Figure 3 and Materials and Methods for derivation). Both
of these proteins interact with HIV-1 IN, but the intracellular locations contrast markedly. GFP-IBD co-localizes with IN but is not chromatin attached,
while LANA31-GFP-IBD is nuclear and clearly tethers IN to chromatin. Mitotic cells are circled. B(ii) Imaging of SupT1 cells stably expressing GFP-IBD
or LANA31-GFP-IBD confirmed that the LANA31 peptide converts GFP-IBD to a chromatin attached molecule. Mitotic cells are designated with arrows.
Note that these cell lines are polyclonal and express variable levels of the GFP fusions. (C) HIV-1 reporter virus challenge. TL4 cells demonstrate a 456-
fold decrease in HIV-1 infectivity. LANA31-GFP-IBD effects a 200-fold rescue, functioning comparably to re-expressed LEDGF/p75 and in contrast to
the LANA31-GFP-IBD
D366N. Error bars reflect duplicate measurements in each experiment. Note that as predicted, re-expression of LEDGF/p75 (by
transduction of the LEDGF/p75 syn7 cDNA) rescues the cells back to the level of inhibition produced by the RNAi alone. Rescuing proteins were
transduced stably with G418-selectable retroviral vectors. (D) Results summarizing multiple experiments (n=6) comparing LANA31-GFP-IBD,
LANA31-GFP-IBD
D366N and LEDGF/p75 are shown. (E) Alu-PCR integration assay confirming rescue of integration in TL4 cells expressing LANA31-GFP-
IBD. (F) LEDGF/p75 mRNA levels in TL4 cell lines, normalized to Cyclophilin A mRNA levels.
doi:10.1371/journal.ppat.1000522.g007
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tution is tolerated in the chromatin side of the LEDGF/p75
mechanism. Docking to either nucleosome core proteins or to
nucleosome linker DNA is effective. More generally, docking to
either DNA or protein molecules in chromatin and docking either
internal to the nucleosome or outside of it is sufficient for the HIV-
1 co-factor activity of LEDGF/p75. Indeed, the experiments with
the minimal construct LANA31-GFP-IBD show that conferring
chromatin attachment is sufficient to switch the phenotype of
GFP-IBD from integration-blocking to integration-facilitating. In
these experiments LANA31-GFP-IBD produced a nearly com-
plete rescue (Figure 7), restoring over two logs of infectivity in these
highly HIV-1-resistant cell lines. This result underscores that
location of the IBD alone in the cell is the paramount factor.
It has been particularly interesting in this and prior studies that
endogenous LEDGF/p75 depletion and IBD over-expression are
multiplicative rather than additive, with each producing about 10-
30 fold inhibition and the combination reaching over three logs of
inhibition. GFP-IBD is dominant interfering rather than dominant
negative, because it does not bind LEDGF/p75. That the same
protein reverses this combined effect when tethered to chromatin
by 31 additional amino acids at the GFP end (and in the presence
of the un-tethered form of GFP-IBD) indicates that the dominant
interference we are observing is not simply due to decreased
catalytic function when GFP-IBD occupies the IN dimer interface
or to lack of coupling to NDE functions. Rather, lack of chromatin
attachment appears to be crucial.
Retrovirologists have long been intrigued by the important
question of how lentiviral pre-integration complex nuclear import
is enabled in nondividing cells [47,48]. However, intensive
intellectual focus on this still unsolved question may have diverted
attention from a more general problem of retroviral chromatin
attachment that has received relatively little investigation yet was
recognized to be both important and unsolved a decade ago [2].
The pre-integration complex is intuitively conceived as the active
directed participant in the infection process. Insights may be
gained by considering the opposite frame of reference, i.e.,
considering the chromatin fiber as a mobile actor. Indeed, recent
nuclear structure/function research provides ample evidence for
dynamic chromatin mobility [49]. Without a means to quickly and
securely latch onto chromatin after nuclear entry, the pre-
integration complex may be at higher risk of attrition. Mammalian
genomes record a vast number of retroelement invasions, with
50% of the human genome recognizably derived from retro-
elements and 8% from endogenous retroviruses [50]. It is likely
that the pre-integration complex is vulnerable to any number of
evolved intra-nuclear host defense mechanisms. It must not only
secure attachment to chromatin, but also avoid sequestration by
other nuclear components, whether these are diffusing macromol-
ecules, more fixed elements of a putative nuclear matrix, or
specifically evolved nuclear restriction activities. Our data suggest
that retroviruses, in common with some large DNA viruses such as
EBV, KSHV, and HPV have a need for a chromatin tethering
mechanism to allow the viral cDNA to become and remain
attached to chromatin as the latter undergoes spatial and/or
compositional change. Certain large DNA viruses such as the
papilloma viruses and persistent episomal herpesviruses (Epstein-
Barr, KSHV) express viral protein tethers that attach their circular
unintegrated episomes to chromatin [44,51–55]. From this
perspective, retroviruses face the same challenge of establishing
and maintaining chromosome association until they achieve
chromosomal integration. Similar studies with chimeric fusions
have clarified the tethering requirements for EBV [53,56].
Despite their diversity, the LEDGF/p75 NDE, H1.1, H1.5 and
the LANA31 peptide have one functional property in common.
Each binds strongly to chromatin in a cell cycle-resilient manner,
trafficking in tight association with both condensed mitotic and
uncondensed chromatin (Figures 2A,B, 3A,B,C,E, 5B, S1A,B and
S2C). LEDGF/p75
PWWP-, in contrast, loses some rescuing ability.
Whether this is due to the specific loss of attachment during the
period when chromatin is most mobile (Figure 10C), or to the
general loss of avidity detected in the chromatin binding assay
(Figure 10A,B,E) is not yet clear. An important aspect to consider
is the dramatic transformations in the structural organization of
both the cytoplasm and the nucleus that accompanies the cell cycle
in higher eukaryotes. Metazoan nuclear envelope reformation
after mitosis does not re-enclose mitotically dispersed components.
Rather, it occurs by end-telophase coating of condensed
chromatin with a lipid membrane bilayer, likely ER-derived,
followed by selective nuclear import to regenerate nuclear
contents. Thus it is a process of selective re-expansion that at
first excludes non-chromatin bound molecules [57–59]. Therefore,
we hypothesize that a retroviral pre-integration complex without a
mechanism to be captured by and stay consistently attached to
chromatin throughout the cell cycle may be at risk of attrition
during mitosis.
Our results do not discount the importance of the NDE, which
merits focused study since the interactions of its elements with
particular ligands may in the future represent therapeutic targets.
While the basic cofactor role is supported without them, NDE
domains surely play more subtle roles in viral replication. One is
already known: the lentiviral bias for integration in transcribed
gene regions is clearly heavily influenced by LEDGF/p75
[6,12,13]. However, this selectivity for active transcription units
might in principle also be supported by other nuclear proteins. We
Figure 8. Chimeric LEDGF/p75 proteins support replicating
HIV-1 infection. (A) TL3 cells expressing GFP-H1.1-199-530 were
challenged with HIV-1 NL4-3 (MOI=0.01). Supernatants were collected
and analyzed for p24. (B) TL4 cell lines expressing LANA31-GFP-IBD or
LANA31-GFP-IBD
D366N were challenged with HIV-1 NL4-3 (MOI=0.3).
Supernatants were collected and analyzed for p24. GFP-IBD is included
for comparison. Cultures were sampled and p24 measured until CPE
became overwhelming.
doi:10.1371/journal.ppat.1000522.g008
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PLoS Pathogens | www.plospathogens.org 11 July 2009 | Volume 5 | Issue 7 | e1000522Figure 9. Chimeric LEDGF/75 proteins function in murine LEDGF/p752/2 cells. (A) GFP-H1.1-199-530 (chimera E) protein localization in
LEDGF/p752/2 MEFs. Images were obtained 24 hours after transfection. (B) Subcellular fractionation of transfected LEDGF/p752/2 MEFs, western
blotting with antiGFP antibody, only S2 fraction shown. GFP-H1.1-199-530 (lane 1) and GFP-H1.1 (lane 2) proteins are indicated. (C) HIV-1 reporter
virus challenge. GFP-H1.1-199-530 rescues HIV-1c-luc in LEDGF/p752/2 cells compared to GFP-H1.1 which does not. No full length LEDGF/p75 mRNA
transcripts were detectable in the LEDGF/p752/2 MEFs (data not shown).
doi:10.1371/journal.ppat.1000522.g009
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PWWP-. (A) LEDGF/p75
PWWP- segregates approximately equally
to S1 and S2 fractions. L1340 cells were transfected with indicated constructs and chromatin separation protocol performed as described. (B) LEDGF/
p75
PWWP- is less resistant than LEDGF/p75 to salt extraction from chromatin. Equal numbers of cells were lysed in CSK I buffer containing graded NaCl
concentrations or in Laemmli buffer (total fraction). LEDGF/p75 PWWP-deleted LEDGF/p75 is fully extracted from the chromatin in the presence of
150 mM NaCl whereas only trace amounts of LEDGF/p75 wild type are released from chromatin at this ionic strength. (C) Immunofluorescence
demonstrates that LEDGF/p75
PWWP- is nuclear (top row) but does not bind to mitotic chromatin (bottom row). (D) TL3 cell lines stably expressing
LEDGF/p75, LEDGF/p75
PWWP-, or LEDGF/p75
IBD- were challenged with HIV-1luc. Luciferase activity was determined 5 days later and levels are
represented as percent of rescue compared to wild type LEDGF/p75. Standard deviations are between fully independent experiments (LEDGF/p75
n=18, LEDGF/p75
PWWP- n=23, LEDGF/p75
IBD- n=10). (E) TL3-derived cell lines in (D) expressing FLAG epitope-tagged LEDGF/p75
PWWP- were
subjected to sub-cellular fractionation as described and immunoblotted with anti-FLAG.
doi:10.1371/journal.ppat.1000522.g010
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yielded LEDGF/p75 as the mediator of chromatin attachment
primarily because it was the best available cellular protein that
binds chromatin with high, cell cycle-resilient avidity and to which
secure IN binding could also evolve without undue constraints on
IN catalysis. It is possible that the other six retroviral genera have
evolved alternative tether mechanisms, especially if — as seems
plausible given their structural differences and the large surface
area involved in the HIV-1 IN dimer-IBD interface — these IN
proteins are constrained functionally from evolving dimer
interfaces that bind the LEDGF/p75 IBD. For example, it has
been suggested that Gag rather than IN serves this role for foamy
retroviruses [60].
In the case of HIV-1, the virus has evolved to engage a protein
with clear modular tethering functions in its normal cellular roles.
This was recently highlighted in several contexts. For example, the
LEDGF/p75 IBD interacts with c-Myc interactor JPO2 [61,62],
as well as the menin/MLL histone methyl transferase complex
[63], and the pogo transposable element with ZNF domain (pogZ)
[64], although the IBD surfaces involved are functionally
distinguishable. Both JPO2 and the menin/MLL complex achieve
chromatin attachment by interacting with LEDGF/p75, and for
menin/MLL oncoproteins this attachment is required for
transformation [62,63]. Fusing the LEDGF/p75 PWWP domain
directly to MLL-ENL abrogates the requirement for either
LEDGF/p75 or menin in MLL-ENL associated oncogenesis
[63]. Thus, the only function of LEDGF/p75 in the trimolecular
complex is to tether menin/MLL-ENL to chromatin [63]
(reviewed in [65]).
Lentiviruses display an approximately two-fold preference for
integrating into active transcription units. This is reduced in
LEDGF/p75-depleted cells [12,13]. Profiling of LEDGF/p75-
depleted cells by microarrays has identified modest changes and
no specific pattern assignable to particular Gene Ontology subsets
suggesting that it does not localize with high specificity [6,12,13].
Thus, this protein is likely to associate fairly ubiquitously with
chromatin and use of LEDGF/p75 may on average tilt the virus
towards transcribed regions favorable for subsequent proviral
transcription. In this regard, it may be that some of the
differences we observed in luciferase expression and even in
integration in cells with introduced chimeras reflect location
effects in which the particular chromatin structure (e.g.,
heterochromatic) may be less hospitable to either integration
itself or to transcription of the integrated provirus. Using ligands
that target ubiquitous chromatin elements (inter-nucleosome
linker DNA segments, core histones), we may be dispersing
integration, and subsequent expression levels of the provirus may
reflect expression from less transcriptionally favorable integra-
tion sites. Answering this question definitively will require the
results of work in progress on full-scale comparisons of genome
wide integration site distributions with each of these alternative
tethers. In addition, more local effects with these artificial tethers
having contrasting topologies of nucleosome engagement may be
revealing. For example, Wang et al. have shown that HIV-1
integration is favored on the outward facing DNA major grooves
of cell nucleosomes [66]. In addition, substituting these
alternative tethers with more focused ones could offer opportu-
nities for lentiviral vector targeting. An in vitro precedent of
concentrating integration at phage lambda repressor sites using a
chimera with the IBD or LEDGF/p75 fused to the repressor
binding domain has been established [67]. The present results
also suggest that the ability of a module, e.g., a designed zinc
finger protein, to bind with substantial affinity may impact
targeting success.
Materials and Methods
Construction of H1.1-LEDGF/p75 and H1.5-LEDGF/p75
chimeras
All LEDGF/p75-chimeric expression constructs used in this
work were derived from p75syn7, which has 7 synonymous RNAi-
blocking nucleotide changes [7]. Well-characterized GFP fusion
proteins (GFP-H1.1 and GFP-H1.5) kindly provided by M.
Hendzel [33,39], were the basis for these constructions. GFP
refers to the fluorescence-enhanced (eGFP) version. The C-
terminal 199–530 amino acids of an shRNA-resistant LEDGF/
p75 cDNA, p75syn7 [19], were amplified with primers 5-
NheL199 (AAG CTA GCG TCG ACA TGG TAA AAC AGC
CCT GTC CTT) and link-Age-3 (TTA CCG GTT TGC TGC
CGC CGC CGC CGG AAT CTA GTG TAG AAT CCT TCA
GAG) and ligated upstream of GFP-H1.1 and GFP-H1.5 using
Nhe I and Age I to generate constructs A and B. Constructs C
and D were constructed similarly using 5 BspESal199 (AAT
CCG GAG TCG ACA TGG TAA AAC AGC CCT GTC CTT
C) and link-BglII-3 (TTA GAT CTG CTG CCG CCG CCG
CCG GAA TCT AGT GTA GAA TCC TTC AGA G) ligated
inframe between eGFP and H1.1 or H1.5 using BspEI and BglII.
For constructs E and F, the stop codon of H1.1 and H1.5 was first
removed using primers 1.5 upstrPST (GCC CAA AGC CAA
GAA GGC AG), 1.5noTAGlkBm (TTG GAT CCG CCG CCG
CCG GAC TTC TTT TTG GCA GCC GCC TTC),1.1-
upstNot (GTG GTG TGT CGT TGG CAG CTC), and
1.1noTAGLkBm (TTG GAT CCG CCG CCG CCG GAC
TTT TTC TTG GGT GCC GCT TTC), followed by PCR
amplification of LEDGF/p75 199–530 using Bam199 (AAG
GAT CCA TGG TAA AAC AGC CCT GTC CTT C) and
Xba530 (TTT CTA GAC TAG TTA TCT AGT GTA GAA
TCC TTC). For retroviral vector expression, constructs E and F
were digested with AgeI, blunted with Klenow polymerase,
digested with XhoI and ligated into the Bam-Sal backbone of
JZ308 [68], generating JZE and JZF. D366N mutants were
generated using overlap extension PCR. All constructs were
confirmed by restriction digests followed by DNA sequencing.
LANA31-LEDGF/p75 chimera
Synthetic oligonucleotides were used to fuse the 31 N-terminal
amino acids of KSHV LANA MAPPGMRLRSGRST-
GAPLTRGSCRKRNRSPE to the N-terminus of p75
P-/DAT2R,
generating LANA31-p75
P-/DAT2R. The functionally critical 23
amino acids mapped by Barbera et al. [29] are underlined. p75
P-/
DAT2R is a LEDGF/p75 chromatin binding domain ensemble
mutant in which (i) the 93 N-terminal amino acids of the PWWP
domain were deleted and (ii) each of the two A/T hooks was
disabled by glycine substitution of a critical arginine residue [69].
p75
P-/DAT2R does not bind chromatin in immunofluorescence
assays that track mitotic chromatin, and displays minimal
chromatin binding in the more stringent chromatin binding assay
described below. Thus, the protein differs from the H1 fusions in
having amino acids 94–198 of LEDGF/p75, except for the Arg to
Gly changes at residues 182 and 196, which produce in each A/T
hook the disabling RGGP instead of RGRP. The chimeric protein
was expressed from a retroviral vector JZ-LANA31-p75
P-/DAT2R,
which was constructed as follows. The LANA31 coding sequence
was synthesized as forward and reverse oligonucleotides flanked by
Bam HI sites (forward-ATATATATATATGGATCCTCGAG-
ATGGCGCCCCCGGGAATGCGCCTGAGGTCGGGACG-
GAGCACCGGCGCGCCCTTAACGAGAGGAAGTTGTAG-
GAAACGAAACAGGTCTCCGGAAGGATCCATAT), (re-
verse-ATATGGATCCTTCCGGAGACCTGTTTCGTTTCC-
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GTCCCGACCTCAGGCGCATTCCCGGGGGCGCCATCT-
CGAGGATCCATATATATATATAT). 100 pmol of each strand
was annealed in STE buffer (10 mM Tris pH 8, 1 mM EDTA
and 50 mM NaCl) by heating to 95uC for 3 minutes and cooling
to room temperature. Annealed oligonucleotides were digested
with Bam HI inserted into the Bam HI site of JZ-p75
P-/DAT2R.
The LANA31-GFP-IBD and LANA31-GFP-IBD
D366N were
generated by PCR from previously described plasmids [7], using
primers 59BamGFPIBD (ATATGGATCCGTGGTGAG-
CAAGGGC) and 39Salp75IBDs (ATATGTCGACCTATCCTT-
CACCAACCAA). LEDGF/p75
PWWP- has been described previ-
ously [25].
LEDGF/p75-targeted RNAi
Studies were conducted in T cell lines rendered endogenous
LEDGF/p75-negative, with depletion effective enough to remove
detectable protein from the S2 chromatin fraction (see the next
section and Table S1 for baseline characteristics of lines used).
RNAi was performed with intensified lentiviral vector-based RNAi
(ilvRNAi) as described in [7] and reviewed in [70]. One adherent
cell line (L cells, described below) was derived alternatively, by
stable plasmid-based RNAi, which is fully adequate to report over-
expressed HIV-1 IN protein phenotypes. Real time quantitative
RT-PCR for LEDGF/p75 mRNA and Cyclophilin A was
performed as described [7].
Cell lines
Human T cell lines were maintained in RPMI with 10% FBS
and 293 T cells were maintained in DMEM with 10% FBS, both
with penicillin, streptomycin and L-glutamine. Main characteris-
tics of T cell lines used in this work are summarized in Table S1.
The previously described TL3 (active LEDGF/p75-targeted
shRNA) and TC3 (control shRNA) lines are derived from SupT1
cells by ilvRNAi [7]. TC3 and TL3 were established simulta-
neously from the same parental population, using equivalent MOI
transduction with lentiviral vectors that differed only in the 19 nt
of the shRNA, followed by equivalent sorting for the co-encoded
mCherry marker. Other pertinent phenotypic properties (growth
rates, cell morphology, cluster size, CD4 and CXCR4 surface
expression, etc.) are indistinguishable [7]. TL2 and TC2 are
equivalent lines with GFP rather than mCherry co-encoded by the
lentiviral vector. GFP-IBD cells stably express GFP fused to the
IBD (amino acids 347–429) [7]. TL4 cells are a SupT1 cell line
derived by an ilvRNAi vector that expresses the LEDGF/p75-
targeting shRNA as well as the dominant-interfering GFP-IBD
protein [7]. Whereas TL2 or TL3 cells displayed a 10–30 fold
reduction in single round HIV-1 reporter virus susceptibility in
HIV-1 infectivity, TL4 cells displayed a 560-fold decrement [7].
Gamma-retroviral (MLV) IN proteins do not interact with
LEDGF/p75 [18] and MLV vectors are unimpeded by LEDGF/
p75 depletion or dominant interference [7]. MLV vectors were
therefore used to stably introduce mutant or chimeric proteins.
After transduction, cells were selected and maintained in 600 mg/
ml of G418. Introduced proteins that contain the LEDGF/p75 C-
terminal region all have 7 synonymous mutations in the shRNA
target site.
L cells are 293T cells depleted of LEDGF/p75 by stable
plasmid-mediated shRNA expression (hygromycin-selected) cyto-
plasm [18]. LH4 cells are 293T cells that stably express Myc
epitope-tagged HIV-1 IN (puromycin-selected) in the L cell
background [19,20]. LH4 cells are maintained in 3 mg/ml
puromycin and 200 mg/ml hygromycin.
Mouse embryonic fibroblasts
LEDGF/p75+/+ and 2/2 mouse embryonic fibroblasts (MEF)
were obtained from Wendy Bickmore [45]. The lentiviral defect in
these cells has been described [13]. The cells used here were
harvested 13.5 dpc and immortalized by repeated passaging.
MEFs were cultured on gelatin coated plates in DMEM with 15%
FBS, 1% NEAA, 7.15 mM beta mercaptoethanol, 1% sodium
pyruvate, 1% glutamine and 1% penicillin/streptomycin.
LEDGF/p752/2 cells were transfected with GFP-H1.1 or
GFP-H1.1-199-530, FACS sorted for GFP expression then either
plated for challenge with HIV-1c-luc, or analyzed for protein
expression after subcellular fractionation. Infectivity was assessed
72 hours after challenge using BrightGlo (Promega) according to
the manufacturer’s instructions, and luciferase activity normalized
to protein content.
Vector production
ilvRNAi vectors were produced as described [7,70]. MLV
vectors were produced in 293T cells by calcium phosphate co-
transfection of the transfer vector with pHIT60 and pMD.G.
Supernatants were collected 48 hours later, filtered (0.45 mM),
concentrated over a sucrose gradient and stored at (2)8 0 uC.
Virus production, quantification, and titration
Full length HIV-1 NL4-3 viruses were generated in 293T
producer cells by calcium phosphate-mediated transfection. Viral
particles were quantified in cell supernatants by HIV-1 p24
antigen capture enzyme-linked immunosorbent assay (Zeptome-
trix, Inc.). Virus titers were determined on GHOST cells.
Assessment of HIV-1 replication
10
6 cells were infected with HIV-1 NL4-3 at MOIs of 0.01 or
0.3 in 3 ml RPMI. Cells were washed 4 times after 16 hours. Cells
were maintained in 6 ml RPMI. Supernatants for p24 measure-
ment were taken in duplicate periodically and HIV-1 p24 antigen
was measured as described above.
Immunoblotting
Total cell lysates were lysed in RIPA (150 mM NaCl, 0.5%
deoxycholate, 0.1% sodium dodecyl sulfate, 1% NP-40, 150 mM
Tris-HCl pH 8.0) with added protease inhibitors (complete-Mini,
Boehringer), clarified, and protein concentration was determined
using the Bradford assay. Fractions and lysates were boiled in
Laemmli with ß-mercaptoethanol for 10 minutes, electrophoresed
on 10% Tris HCl gels (Biorad) and transferred overnight to
Immobilon P membranes (Millipore). Blocked membranes were
incubated overnight with primary antibodies as follows: anti-GFP
(Clontech, JL8) 1:5000, anti-myc (9e10, Covance) 1:500, rabbit
anti-myc (Santa Cruz) 1:500, anti-LEDGF/p75 mAb (BD
Biosciences 611714) 1:500, rabbit anti-LEDGF/p75 (Bethyl
Laboratories A300-848A), anti-LEDGF/p75 (Cell Signaling
Technologies) 1:500, or mAb to alpha-tubulin (clone B-5-1-2,
Sigma) 1:8000.
Chromatin fractionation and salt extraction assays
The fractionation protocol has been characterized extensively
[7,25]. Briefly, cells were lysed for 15 min on ice in cold CSK I
buffer (10 mM Pipes, pH 6.8, 100 mM NaCl, 1 mM EDTA,
300 mM sucrose, 1 mM MgCl2, 1 mM DTT) supplemented with
0.5% Triton X-100 and protease inhibitors (Roche Complete
Mini). Lysates were centrifuged at 5006g at 4uC for 3 min. The
supernatant (S1 fraction) contains Triton-soluble proteins. The
pellet (P1) was resuspended in CSK II buffer (10 mM Pipes,
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DTT), treated with DNase (1 unit/100 ml) for 30 min, followed by
extraction with 250 mM NH2SO4 for 10 min at 25uC. The
DNase- and salt-treated sample was centrifuged at 1,2006g for
6 min at 4uC and the supernatant (S2 fraction, containing released
chromatin-associated proteins) was collected. The S1 and S2
fractions were analyzed by immunoblotting. P2, which contains
non-chromatin bound, Triton-insoluble nuclear proteins such as
those comprising the nuclear matrix, and is LEDGF/p75-
negative, was not analyzed here. For testing graded NaCl
concentrations, 6610
6 cells were centrifuged at 1000 g for 6 min
at 4uC and pellets were resuspended in 100 ml of CSK I buffer
supplemented with protease inhibitors and varying concentrations
of NaCl. A total fraction was obtained by re-suspending in 100 ml
of Laemmli buffer. After 15 min incubation on ice, the samples
were centrifuged at 16,000 g for 2 min at 4uC. Twenty ml of each
supernatant was analyzed by immunoblotting.
Immunoprecipitation
30 ml of Dynal Dynabeads Sheep anti-mouse IgG (product
no. 110.31) were blocked in 10% milk in Tris buffered Saline with
0.1% Tween (TBST) by rotating for 1.5 hours at 4uC. 2.8610
6
LH4 cells were plated in T 75 flasks, and transfected the next day
with 10 mg of the chimeric proteins and 3.5 mg of HIV-1 IN Myc.
48 hours after transfection the cells were scraped off the flasks and
lysed for 30 minutes in CSKII buffer [7] with DNase. One third
volume of 1 M Ammonium sulfate was added and lysates incubated
at RT for an additional 30 minutes, then centrifuged at 1300 g for
6 minutes. 500 ml of the cell lysate was incubated with3 mg of either
a monoclonal GFP antibody (BD Biosciences living colors ref.
no 632381) or monoclonal LEDGF/p75 antibody (BD Biosciences
cat no. 611714) or isotype control for one hour on ice. This was
then mixed by continuous rotation with the pre-blocked beads
overnight at 4uC. Beads were washed three times with PBS, eluted
in 50 mlo f2 6 Laemli buffer and boiled for 7 minutes at 95uC
before being analysed by western blotting as described above.
Immunofluorescence and confocal microscopy
Two mg of each plasmid was transfected into cells plated in
Labtek II chamber slides (1610
5 cells/well). Cells were fixed with
fresh 4% formaldehyde in PBS for 10 minutes at 37uC, washed
with PBS and permeabilized with ice cold methanol for two
minutes at room temperature. Fixed cells were blocked in 10%
FCS, 20 mM ammonium chloride and PBS for thirty minutes,
incubated with the appropriate primary antibodies for two hours,
washed in PBS then incubated for one hour with Alexa 594 or 488
secondary antibodies (Invitrogen, diluted 1:1000). Cells were
washed again with PBS and Prolong Gold mounting solution plus
DAPI added. Confocal images were obtained using an LSM 510
device as described [19]. To image T cells, 0.5610
6 cells were
fixed in 4% formaldehyde as described, washed once in PBS then
resuspended in 100 ml of PBS. The cell suspension was placed into
a cytofunnel (Shandon Single Cytofunnel Cat. no. 132619) on a
slide, (Superfrost Plus, Fisher Brand Cat. no. 22-034-979),
clamped into a metal cytospin holder and spun at 600 rpm for
5 minutes. Cells were mounted with Prolong Gold with DAPI and
imaged using confocal microscopy.
HIV-1 reporter virus production, challenge and
integration assays
HIVluc is HIV-1 NL4-3 that encodes firefly luciferase in the nef
ORF; 426 nt of env are also deleted as described [7]. HIV-1c-luc
has been described previously [7]. VSV-G pseudotyped reporter
virus was produced in 293T cells by calcium phosphate
transfection and stocks were treated with PfuTurbo DNase at
37uC for 45 minutes. Reverse transcriptase (RT) activity was
determined in a TopCount NXT microplate luminescence-
scintillation counter (Packard) as described [71]. To gauge
preparation quality and virus inputs appropriately, RT activities
were compared to a known HIV-1 standard titered on SupT1 cells
and luciferase activity per RT unit was determined on SupT1 cells.
Challenged cells were harvested 5–7 days after infection except
where indicated otherwise, for both luciferase activity (Steady Glo,
Promega) and DNA extraction for real-time quantitative PCR
assays using the Roche LightCycler [7]. Control cells used were
either the TC3 or parental SupT1 cell lines, and all luciferase
values were normalized to cell number. Alu element-U3 PCR and
mitochondrial DNA PCR were performed as described [7].
Supporting Information
Figure S1 Confocal microscopy of linker histone and LANA31
fusion proteins. (A) H1 fusions and control proteins. See Figure 1
for protein architecture. Proteins were expressed in 293T cells and
GFP and DNA (DAPI) were co-imaged. Mitotic cells are
highlighted by circling. GFP-199-530 is cytoplasmic and not
chromatin bound. GFP-H1.1 and GFP-H1.5 are exclusively
nuclear and chromatin bound. The GFP-H1 fusions are also
tethered to chromatin throughout the cell cycle. (B) Immunoflu-
orescence microscopy of p75
P-/DAT2R and LANA31-p75
P-/DAT2R
in L cells. Although nuclear in location by virtue of the retained
LEDGF/p75 NLS, p75
P-/DAT2R does not overlap with DAPI and
is not tethered to chromatin. In contrast, LANA31-p75
P-/DAT2R
overlaps with DAPI, and remains tethered to mitotic chromatin
throughout the cell cycle. This can even be appreciated in the
interphase cells (second panels from left) where p75
P-/DAT2R is
diffusely and homogenously distributed in the nucleus and
LANA31-p75
P-/DAT2R is variegated.
Found at: doi:10.1371/journal.ppat.1000522.s001 (0.97 MB TIF)
Figure S2 Chimera function analysis at different time points. (A)
Luciferase expression in TL3 cells stably expressing GFP-H1.5-
199-530 (construct F) analyzed 24 hours after challenge with
HIVluc. (B) Luciferase expression in TL3 cell lines stably
expressing GFP-H1.1-199-530 (construct E) or GFP-H1.5-199-
530 (construct F) analyzed two months after challenge with
HIVluc. (C) Subcellular fractions from stable cell lines expressing
GFP-H1.1-199-530 or GFP-H1.5-199-530 (analyzed with anti-
GFP antibody) or LANA31-p75
P-/DAT2R (analyzed with anti-
LEDGF/p75 antibody).
Found at: doi:10.1371/journal.ppat.1000522.s002 (0.26 MB TIF)
Figure S3 GFP-IBD interacts with IN and blocks HIV-1
infection. (A) GFP-IBD and IN were expressed by plasmid co-
transfection in L cells and imaged by confocal microscopy.
Circling highlights a metaphase cell. (B) HIVluc infection of the
indicated cell lines. Luciferase activity was measured at 5 days.
Found at: doi:10.1371/journal.ppat.1000522.s003 (0.46 MB TIF)
Figure S4 Immunoblotting of sub-cellular fractions from stable cell
lines. (A) GFP-H1.5-199-530 was stably expressed in cells previously
engineered to express GFP-IBD [6]. (B) LANA31-p75
P-/DAT2R was
stably expressed in TL4 cells. The results confirm that the H1 and
LANA31 chimeras are confined to the chromatin-bound S2 fraction,
while GFP-IBD is found in the non-bound S1 fraction.
Found at: doi:10.1371/journal.ppat.1000522.s004 (0.19 MB TIF)
Figure S5 Cellular localization of GFP-IBD spectral variants.
LANA31-GFP-IBD and mCherry-IBD (or CFP-IBD, data not
shown) do not colocalize.
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Figure S6 Immunoblotting of sub-cellular fractions of TL4 cells.
Western blotting of TL4 cells expressing LANA31-GFP-IBD or
LANA31-GFP-IBD
D366N confirms that there is no detectable
endogenous LEDGF/p75 in the S2 fractions.
Found at: doi:10.1371/journal.ppat.1000522.s006 (0.08 MB TIF)
Table S1 Baseline characteristics of stable human T cell lines.
Found at: doi:10.1371/journal.ppat.1000522.s007 (0.03 MB
DOC)
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